To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Toward clinically applica… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Toward clinically applicable biomarkers for asthma: An EAACI position paper

Journal article
Authors Z. Diamant
S. Vijverberg
K. Alving
A. Bakirtas
L. Bjermer
A. Custovic
S. E. Dahlen
M. Gaga
R. G. van Wijk
S. Del Giacco
E. Hamelmann
L. G. Heaney
E. Heffler
Kalayci, Kalayci,
K. Kostikas
R. Lutter
Anna-Carin Olin
S. Sergejeva
A. Simpson
P. J. Sterk
E. Tufvesson
I. Agache
S. F. Seys
Published in Allergy
Volume 74
Issue 10
Pages 1835-1851
ISSN 0105-4538
Publication year 2019
Published at Institute of Medicine, Department of Public Health and Community Medicine, Section of Occupational and environmental medicine
Pages 1835-1851
Language en
Subject categories Respiratory Medicine and Allergy


Inflammation, structural, and functional abnormalities within the airways are key features of asthma. Although these processes are well documented, their expression varies across the heterogeneous spectrum of asthma. Type 2 inflammatory responses are characterized by increased levels of eosinophils, FeNO, and type 2 cytokines in blood and/or airways. Presently, type 2 asthma is the best-defined endotype, typically found in patients with allergic asthma, but surprisingly also in nonallergic patients with (severe) asthma. The etiology of asthma with non-type 2 inflammation is less clear. During the past decade, targeted therapies, including biologicals and small molecules, have been increasingly integrated into treatment strategies of severe asthma. These treatments block specific inflammatory pathways or single mediators. Single or composite biomarkers help to identify patients who will benefit from these treatments. So far, only a few inflammatory biomarkers have been validated for clinical application. The European Academy of Allergy & Clinical Immunology Task Force on Biomarkers in Asthma was initiated to review different biomarker sampling methods and to investigate clinical applicability of new and existing inflammatory biomarkers (point-of-care) to support diagnosis, targeted treatment, and monitoring of severe asthma. Subsequently, we discuss existing and novel targeted therapies for asthma as well as applicable biomarkers.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?